Physician profile
Chad A Prior
NPI 1790772036
$9,332.52
in general payments reported to CMS, 2019-2025
45 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $1,053 · 2021: $1,528 · 2022: $1,522 · 2023: $1,196 · 2024: $1,562 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,938.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,418.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,415.04 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $826.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $601.17 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $558.26 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $471.73 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $357.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.26 | 2019-2022 | |
| Pfizer INC. | $319.42 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $291.10 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $244.54 | 2019-2025 | |
| Astellas Pharma US INC | $223.00 | 2020-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $203.32 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.64 | 2019-2024 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $169.37 | 2021-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $155.07 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $136.41 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Mylan Specialty L.P. | $122.44 | 2019-2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $108.15 | 2019-2022 | |
| Abbott Laboratories | $106.47 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $104.22 | 2020-2022 | |
| Boston Scientific Corporation | $103.46 | 2021-2025 | Watchman Flx |
| Exact Sciences Corporation | $93.60 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $89.77 | 2019-2022 | |
| Viatris Specialty LLC | $71.31 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $64.52 | 2020-2022 | |
| Allergan, INC. | $63.10 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.69 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $55.97 | 2019-2020 | |
| Sanofi Pasteur INC. | $51.51 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $44.05 | 2024-2025 | Zenpep |
| Ucb, INC. | $35.94 | 2020-2021 | |
| Almatica Pharma LLC | $31.31 | 2023-2024 | Loreev Xr, Teriparatide |
| Xeris Pharmaceuticals, INC. | $29.23 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $29.14 | 2021 | |
| Inspire Medical Systems, INC. | $27.99 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $22.06 | 2019 | |
| Globus Medical, INC. | $19.62 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $18.21 | 2022 | |
| Tactile Systems Technology INC | $16.10 | 2024 | Entre Plus, Flexitouch Plus |
| Corium, LLC | $14.91 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $14.86 | 2024 | Unithroid |
| Lundbeck LLC | $14.81 | 2024 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $12.47 | 2019 | |
| Eisai INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Prior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.